EGFR Inhibitors Enhanced the Susceptibility to NK Cell-mediated Lysis of Lung Cancer Cells
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
As quercetin, which can inhibit phosphatidylinositol 3-kinase, nuclear factor-kappa B, and protein kinase C (PKC) pathways, induced expression of natural killer group 2, member D (NKG2D) ligands on cancer cells and made the cells sensitive to NK -cell-mediated killing; inhibition of epidermal growth factor receptor (EGFR) pathway might lead to induction of NKG2D ligands. In this study, it was investigated whether EGFR inhibitors, including erlotinib or gefitinib, could regulate expression of NKG2D ligands in various lung cancer cells including A549, NCI-H23, and SW-900. The EGFR inhibitors predominantly increased transcription and surface expression of ULBP1, and subsequently increased susceptibility of the cancer cells to NK-92 cells. When the selective inhibitors of nuclear factor-kappa B, phosphatidylinositol 3-kinase, mitogen-activated protein kinases, and PKC were treated to discriminate downstream signaling of EGFR pathway, expression of ULBP1 in the cancer cells was induced by inhibition of PKC. Treatment with phorbol 12-myristate 13-acetate restored the EGFR inhibitor-induced ULBP1 transcription. Binding activity to ULBP1 promoter region of AP-2α, which suggested as suppressor of expression of ULBP1, was decreased by treatment with EGFR inhibitors, and restored by pretreatment with phorbol 12-myristate 13-acetate in A549 and SW-900. Rottlerin, a PKCδ inhibitor, also decreased the binding activity of AP-2α in dose-dependent manner. This study suggests that EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells by induction of ULBP1 by inhibition of PKC pathway and therapeutic efficacy of EGFR inhibitors in lung cancer may be mediated in part by increased susceptibility to NK cell-mediated cytotoxicity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NKAL upregulation by NSCLC cells, linked to enhanced NK-mediated ADCC”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Kim et al., 2011
Citations
Cites
1 retracted
Gadgeel, S. M., Ali, S., Philip, P. A., Wozniak, A., & Sarkar, F. H. (2009) · Cancer · doi:10.1002/cncr.24250 · Cited by 79
RetractedActivation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308
Recognition of Stress-Induced MHC Molecules by Intestinal Epithelial γδ T Cells
Groh, V., Steinle, A., Bauer, S., & Spies, T. (1998) · Science · doi:10.1126/science.279.5357.1737 · Cited by 1,142
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083 · cited 1×
“An activating receptor NKG2D (natural killer group 2, member D) is expressed on human NK cells, CD8 T lymphocytes and gd T lymphocytes(7,12) and it has been known that the binding of NKG2D to its ligands may activate NK and T cells, and promote cytotoxic lysis of the target cells.(13) Eight distinct NKG2D ligands in h…”
BackgroundGroh, V, Bahram, S., Bauer, S., Herman, A., Beauchamp, M., & Spies, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12445 · Cited by 1,017
Cited by
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
“…et al., 2010 Stagg et al., 2011 Erlotinib human cancer cells upregulates NKG2D ligands results in increased susceptibility to NK cell cytotoxicity Kim et al., 2011 immortalized human monocytes inhibits differentiation may favor the accumulation of MDSCs in cancer patients Savikko et al.,…”
BackgroundImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175
“5-Fluorouracil (34), gemcitabine (35, 36), gefitinib (39, 40), erlotinib (yet another clinically used EGFR inhibitor; ref.”
BackgroundTargeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Otano, I., Ucero, A. C., Zugazagoitia, J., & Paz-Ares, L. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00718-x · Cited by 184
Metadata
- Authors
- Kim, H., Kim, S.-H., Kim, M.-J., Kim, S.-J., Park, S.-J., Chung, J.-S., Bae, J.-H., & Kang, C.-D.
- Affiliations
- Pusan National University (KR)
- Corresponding author
- Kim, Sun-Hee
- Kim, Mi-Ju
- Bae, Jae-Ho
- Kang, Chi-Dug
- Venue
- Journal of Immunotherapy
- Published
- 2011-05
- Volume
- 34
- Issue
- 4
- Pages
- 372-381
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W2032998398
- Cited by
- 63
- References
- 66
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 8 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 3 · 2013: 4 · 2012: 2
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Immunotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- EGFR inhibitors, lung cancer, NK cell cytotoxicity, NKG2D ligands, ULBP1, protein kinase C, erlotinib, gefitinib, quercetin, phorbol myristate acetate, rottlerin, NK cell therapy
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Cytotoxicity, Immunologic, Humans, Killer Cells, Natural, Lung Neoplasms, Protein Kinase C, Quinazolines, Signal Transduction, Gene Expression Regulation, Neoplastic, Intercellular Signaling Peptides and Proteins, Cell Line, Tumor, Protein Kinase Inhibitors, Intracellular Signaling Peptides and Proteins, Transcription Factor AP-2, GPI-Linked Proteins, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EGFR Inhibitors Enhanced the Susceptibility to NK Cell-mediated Lysis of Lung Cancer Cells. https://app.cochat.ai/papers/10.1097/cji.0b013e31821b724a
- The paper
- Kim, H., Kim, S.-H., Kim, M.-J., Kim, S.-J., Park, S.-J., Chung, J.-S., Bae, J.-H., & Kang, C.-D. (2011). EGFR Inhibitors Enhanced the Susceptibility to NK Cell-mediated Lysis of Lung Cancer Cells. Journal of Immunotherapy. https://doi.org/10.1097/cji.0b013e31821b724a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.